Dhesh Govender Calls Halted Avastin Trial 'Minor' for Genentech
- Bloomberg
Michael King, Analyst, Rates Genentech 'Market Perform': Video
Cuba's cancer drug breakthrough
Stories of Strength: Making the Decision to Enter a Lung Cancer Clinical Trial
Dr. Jakob Dupont describes how rewarding it is to work on clinical trials at Genentech
Warning about Tracheoesophageal Fistula with Avastin
Warning graphic images - Trachea transplant first
Previous Page
Next Page
Dhesh Govender Calls Halted Avastin Trial 'Minor' for Genentech
Dhesh Govender, an analyst at Monness Crespi Hardt & Co., talks with Bloomberg's Brian Sullivan in New York about Genentech Inc.'s decision to stop one of its Avastin trials, the company's stock and drug development. Shares of Genentech Inc., the world's second-biggest biotechnology company, fell the most in two years after first-quarter sales stalled and researchers halted a clinical study of Avastin in patients with a form of lung cancer. (Source: Bloomberg)
Bloomberg | March 23, 2007
